Osteogenic differentiation of human mesenchymal stem cells using RGD-modified BMP-2 coated microspheres.
Micro-structured scaffolds formed with poly(lactic- co -glycolic acid) (PLGA) microspheres were composed of adhesion molecules and growth factors. PLGA microspheres, constructed with Arg-Gly-Asp (RGD) peptide and bone morphogenic protein 2 (BMP-2) were created as a stem cell delivery vehicle. In this study, a high potential for cell adhesion and differentiation of human mesenchymal stem cells (hMSCs) was achieved by constructing the scaffolds with different compositions of coating materials. Specific gene and protein detection by RT-PCR and western blot analysis of the embedded hMSCs revealed that a combination of RGD peptide and BMP-2 induced differentiation of bone cells. Histology and immunohistochemistry results confirmed that bone cell-differentiated transplanted hMSCs were present in the micro-structured scaffolds. The results of this study demonstrate that the regulation of stem cell differentiation by adhesion molecules and growth factors has the potential to enable formation of therapeutic vehicles for the delivery of stem cells that are easily fabricated, less expensive, and more easily controlled than currently available delivery systems. The micro-structure typed PLGA microspheres used in this study possessed unique properties of ideal scaffolds. The embedded hMSCs easily adhered onto the PLGA microspheres mediated by RGD peptide, proliferated well onto the scaffolds, and differentiated to perform the distinct functions of bone tissues.
Department of Biomedical Science, College of Life Science, CHA University 606-16, Yeoksam 1-dong, Kangnam-gu, Seoul 135-081, Republic of Korea.
Ji S
JS
Park
Han N
HN
Yang
Su Y
SY
Jeon
Dae G
DG
Woo
Kun
K
Na
Keun-Hong
KH
Park
D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D006801:Humans; D019344:Lactic Acid / Q000494:pharmacology; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects*; D051379:Mice; D008819:Mice, Nude; D018613:Microscopy, Confocal; D008863:Microspheres; D009842:Oligopeptides / Q000494:pharmacology*; D010012:Osteogenesis / Q000187:drug effects*; D011100:Polyglycolic Acid / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013499:Surface Properties / Q000187:drug effects
D055396:Bone Morphogenetic Protein 2; D020099:Coated Materials, Biocompatible; D009842:Oligopeptides; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C047981:arginyl-glycyl-aspartic acid; D003907:Dexamethasone